The antibiotic problem

Chapter 12 of Peptide Nano-Chemistry and Nanotechnology opens with the scale of what antibiotics achieved. It states that since Alexander Fleming's discovery in 1928, antibiotics have transformed medicine, enabling cancer treatment, organ transplants and open-heart surgery, and have extended the average human lifespan by at least 23 years.

Then comes the problem. Overuse and misuse, the chapter gives the example of penicillin prescribed for a common cold, have driven the rise of multidrug-resistant bacteria. At the same time, the development of new antibiotics has slowed. The chapter lists four alternatives being explored: probiotics, phage therapy, traditional medicine, and antimicrobial peptides. This part is about the last one.

Nature's own antibiotics

Antimicrobial peptides are part of the innate immune system across almost all life. The chapter describes them as essential molecular barriers in the host's natural defence against pathogens. In mammals, they are found mainly in the granules of neutrophils (a type of white blood cell) and in the secretions of the cells lining the skin and mucous surfaces.

The chapter makes a striking point about their importance: mice genetically engineered to lack the mouse version of the human antimicrobial peptide LL-37 are more susceptible to infection, and humans with conditions linked to reduced antimicrobial peptide production, such as atopic dermatitis (eczema), are too.

A short history

The chapter's history section is one of the most readable parts of the book:

  • 1939: René Dubos extracted gramicidin from the soil bacterium Bacillus brevis and showed it protected mice from pneumococcal infection. It became, the chapter says, the first commercialised antimicrobial peptide, used topically for wounds and ulcers.
  • 1939: Lactoferrin, an antimicrobial protein, was isolated from cow's milk.
  • 1941: Tyrocidine was found, active against many microbes but toxic to human blood cells.
  • 1941: Purothionin was found in wheat.
  • The first animal-derived ones, defensins, were found in rabbit white blood cells.
  • 1962: Bombinin from the skin of a frog.
  • 1981: Hans Boman found cecropins in the silk moth, the first reported α-helical antimicrobial peptides.
  • 1987: Michael Zasloff isolated magainins from the skin of the African clawed frog.

Frogs feature twice for a reason. Amphibian skin is a rich source, because frogs live in wet, microbe-rich environments and rely heavily on these chemical defences.

Four shapes

The chapter sorts antimicrobial peptides by structure:

  • α-helical peptides, the largest and most studied group (magainins, cecropins, LL-37). Often floppy in water, they fold into a helix when they meet a bacterial membrane.
  • β-sheet peptides, usually held in shape by disulfide bridges (defensins, tachyplesins, protegrin, polymyxin B).
  • Loop or hairpin peptides, stabilised by one to four disulfide bonds, which also help them resist enzymes.
  • Extended peptides, rich in proline, tryptophan or arginine, with no regular structure. These often slip inside bacteria and attack internal targets, such as the chaperone proteins that help other proteins fold.

Two ways to kill

The chapter divides antimicrobial peptides by how they kill.

Membrane-disruptive peptides break the bacterial membrane, as Part 3 of this series described in detail.

Non-membrane-disruptive peptides get inside and attack internal processes. The chapter gives examples: buforin II passes through the membrane and binds DNA and RNA. Polyphemusin enters E. coli without damaging its membrane. Some proline-rich peptides use specific bacterial transporters to get in, which the chapter explains is why they work better against Gram-negative bacteria (which have those transporters) than Gram-positive ones (which lack them).

The chapter also explains why Gram-negative bacteria are harder to kill: they have a second, outer membrane rich in negatively charged molecules linked by calcium and magnesium, which forms a barrier to many drugs.

Where they are already used

The chapter notes two antimicrobial peptides approved as food additives: nisin, widely used to preserve cheese and processed foods, and ε-polylysine. They are also being explored in animal feed as a way to reduce antibiotic use in livestock.

In medicine, the chapter is candid: although more than five thousand antimicrobial peptides have been discovered since 1939, very few are used in medicines, and those that are have mostly been in topical ointments and similar formulations. Polymyxins, which the chapter lists among the β-sheet group, are a notable exception, used as last-resort injected antibiotics against some resistant infections, though they carry kidney and nerve toxicity.

Why so few medicines?

The chapter's conclusion names the problem directly: high cost and low stability in enzymatic environments. Peptides are expensive to manufacture compared with many small-molecule antibiotics, and the body's enzymes break them down. Add the toxicity issue from Part 3, and the path from promising lab result to injectable drug is steep.

The chapter ends optimistically, suggesting advances in biotechnology may soon remove these limits and make antimicrobial peptides mainstream.

Why this matters to you

Antimicrobial peptides are one of the most important stories in modern medicine that most people have never heard. Your own body relies on them every day. Frogs, moths and soil bacteria have used them for millions of years. And with antibiotic resistance rising, they are among the most hopeful alternatives.

They also illustrate a lesson that runs through every series on this blog: a molecule that works brilliantly in nature, or in a lab dish, still has to survive cost, stability and safety before it becomes a medicine. The next part looks more closely at how this book handles that gap.

This series explains biomedical research for general readers. Most approaches described are at the laboratory or animal study stage and are not available treatments. Nothing here is medical advice.